Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 8 clients • 9 examiners • 8 art units • 0 of 9 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Baker Donelson operates in the Biotechnology & Pharmaceuticals technology area. The firm has handled 2412 career applications and maintains a resolved allowance rate pct of 86.43. This success rate demonstrates the firm's proficiency in securing patent rights for its clients in the life sciences. The 86.43 percent allowance rate is a key indicator of the firm's results. Practitioners can look to this historical success rate when assessing the firm's prosecution capabilities.
There are 7 pending office actions currently being addressed. The firm averages 3.15 office actions per allowance, which serves as a measure of its prosecution efficiency. This 3.15 average helps in setting expectations for the number of interactions required to reach a final decision. With 2412 applications in its history, the firm has established a clear performance record. The 7 pending actions represent the current active workload for the firm's practitioners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (11%) |
| §112 only | 1 (11%) |
| Double-patenting + other | 5 (56%) |
| Multi-statute (no §101) | 1 (11%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 70.8% | +31.8% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692097 | ANTI-CD3 ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | — |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | OUSPENSKI, ILIA I | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | MONTANARI, DAVID A | 7d |
| 18691908 | SOLID FORM OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, PREPARATION METHOD AND USE THEREOF | MOU, LIYUAN | — |
| 18692097 | ANTI-CD3 ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | — |
| 18472411 | MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS | ALSOMAIRY, SARAH ABDOALATIF | — |
| 18150917 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | JADHAO, SAMADHAN JAISING | — |
| 17920445 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CANELLA, KAREN A | — |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | OUSPENSKI, ILIA I | — |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | PECKHAM, RICHARD GRANT | — |
| Client (Assignee) | Pending OAs |
|---|---|
| BEIJING TIDE PHARMACEUTICAL CO., LTD. | 2 |
| ADIMAB LLC | 1 |
| Pharmacosmos Holding A/S | 1 |
| Dartmouth College | 1 |
| Precision Biologics, Inc. | 1 |
| Chinese Academy of Sciences | 1 |
| Immunext, Inc. | 1 |
| Johnson & Johnson | 1 |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1623 | 1 |
| 1632 | 1 |
| 1646 | 1 |
| 1672 | 1 |
| 1643 | 1 |
| 1644 | 1 |
| 1627 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18691908 | SOLID FORM OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18692097 | ANTI-CD3 ANTIBODIES | Adimab, LLC | EDGINGTONGIORDANO, FRANCESCA | §102§112Other | Non-Final OA | — | Pending | Mar 14, 2024 | |
| 18294572 | IRON COMPLEX COMPOUNDS FOR SUBCUTANEOUS USE IN THERAPY OF IRON DEFICIENCY IN COMPANION ANIMALS | Pharmacosmos Holding A/S | BERRY, LAYLA D | 1623 | §102§103§112DP | Non-Final OA | 83d | Pending | Feb 02, 2024 |
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | The Trustees of Dartmouth College | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | 7d | Pending | Nov 13, 2023 |
| 18472411 | MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS | Precision Biologics, Inc. | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §102§112DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18150917 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | Institute Of Zoology, Chinese Academy Of Sciences | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Aug 03, 2023 |
| 17920445 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Immunext, Inc. | CANELLA, KAREN A | 1643 | §112DP | Non-Final OA | — | Pending | Oct 21, 2022 |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Janssen Pharmaceuticals, Inc. | OUSPENSKI, ILIA I | 1644 | §101Other | Non-Final OA | — | Pending | Oct 11, 2022 |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | BEIJING TIDE PHARMACEUTICAL CO., LTD. | PECKHAM, RICHARD GRANT | 1627 | — | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial